By Fineline Cube 
Shanghai-based BioTroy Therapeutics, a cancer immunotherapy developer, has reportedly secured over RMB 200 million (USD 28 million) in a Series A financing round. The round was led by Lapam Capital, with participation from Shanghai Sci-Tech Innovation Center Capital, Shanghai Pudong Venture Capital, and existing shareholders Shanghai Shangshi Capital and Co-win Ventures.
Funding Purpose
The proceeds will primarily be used to accelerate regulatory clinical trials for BioTroy’s first-in-class CD3L1-targeting anti-tumor drug and to expand its R&D pipeline for multiple novel oncology targets.
Company Focus
BioTroy is a clinical-stage biopharma dedicated to addressing global therapeutic challenges, including PD-1/L1 resistance and the remodeling of immunologically “cold” tumor microenvironments.
Clinical Progress
Its CD3L1-targeted drug is currently undergoing multi-center Phase I trials for various solid tumors and hematologic malignancies. The drug has received clinical clearance from both the US FDA and China NMPA.-Fineline Info & Tech